ALISO VIEJO, Calif.–(BUSINESS WIRE) December 23, 2024 — Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal…Original Article
Glaukos Submits New Drug Application to U.S. FDA for Epioxa
